Lonza has entered into a manufacturing agreement with Forty Seven, a Palo Alto, California-based clinical-stage immuno-oncology company, for the clinical supply of Forty Seven’s therapeutic antibodies. Under the agreement Lonza will manufacture material at its Slough, UK facility for Forty Seven’s ongoing and future clinical trials.

Forty Seven’s lead molecule, Hu5F9-G4, is a humanized monoclonal antibody against human CD47 that potentially has broad applications for multiple tumor types and treatment modalities, according to the company. Lonza had previously performed cell-line development for Hu5F9-G4 and, under this new agreement, will optimize the process for the production of Hu5F9-G4 in a 1,000-liter single-use bioreactor.

The manufacturing agreement provides Forty Seven access to multiple batches in Lonza’s single-use bioreactor suites for a five-year term. The agreement applies a new business model for development-stage companies and provides flexible access to capacity that can be used for clinical supply of their pipeline.

Source: Lonza